Malignant mesothelioma: predictors of prognosis and clinical trials

The prognostic scoring systems used were the European Organization for Research and Treatment of Cancer (EORTC) system 11 and the US Cancer and Leukemia Group B (CALGB) system. 12 The EORTC system defines a high risk group of patients according to several factors: poor performance status, high white...

Full description

Saved in:
Bibliographic Details
Published inThorax Vol. 55; no. 9; pp. 725 - 726
Main Authors STEELE, J P C, RUDD, R M
Format Journal Article
LanguageEnglish
Published England BMJ Publishing Group Ltd and British Thoracic Society 01.09.2000
BMJ Publishing Group LTD
BMJ Group
Subjects
Blood
Chemotherapy
Clinical trials
Humans
Lymphatic system
Medical imaging
Medical prognosis
Mesothelioma
Mesothelioma - pathology
Mesothelioma - therapy
Mortality
Multivariate analysis
Neoplasm Staging - methods
Prognosis
Radiation therapy
Surgery
United Kingdom > UK
Online AccessGet full text

Cover

More Information
Summary:The prognostic scoring systems used were the European Organization for Research and Treatment of Cancer (EORTC) system 11 and the US Cancer and Leukemia Group B (CALGB) system. 12 The EORTC system defines a high risk group of patients according to several factors: poor performance status, high white blood cell count at diagnosis, probable or possible (uncertain) histology, male sex, and sarcomatous cell type. Poor prognosis factors by multivariate analysis of the Leicester patients were sarcomatous cell type, low haemoglobin, high white blood cell count, poor performance status, and male sex.
Bibliography:href:thoraxjnl-55-725-2.pdf
istex:FA28E9F017D094A0EA435227DE91C3FEFB0D1D32
ark:/67375/NVC-XQ4KB5GT-Q
local:thoraxjnl;55/9/725a
PMID:10950886
SourceType-Other Sources-1
ObjectType-Article-2
content type line 63
ObjectType-Feature-1
ObjectType-Editorial-4
ObjectType-Commentary-3
ISSN:0040-6376
1468-3296
DOI:10.1136/thorax.55.9.725a